Introduction
============

The stomach is the most frequent site of malignant lymphoma involving the gastrointestinal (GI) tract. Among the subtypes of malignant lymphoma, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) and diffuse large B-cell lymphoma (DLBCL) account for \>90% of all cases ([@b1-ol-0-0-8744]). The incidence of Follicular lymphoma (FL), whether primary or otherwise, has been reported to account for between 0.8 and 3% of gastric lymphomas ([@b2-ol-0-0-8744]). FL is one of the most common types of non-Hodgkin lymphoma in western countries including United States of America ([@b3-ol-0-0-8744]) and United Kingdom ([@b4-ol-0-0-8744]), whereas the incidence in Asian countries including Korea ([@b5-ol-0-0-8744]), Japan ([@b6-ol-0-0-8744]) and China ([@b7-ol-0-0-8744]) is lower than that of western countries. The incidence of FL is typically low in Korea, occupying \~2.9% of malignant lymphoma ([@b8-ol-0-0-8744]).

Histologic features of FL are characterized by nodular aggregation of two different types of tumor cells, which are small cleaved centrocytes and large centroblasts, and WHO histologic grading system is based on the number of centroblasts per high power field ([@b9-ol-0-0-8744]). Clinically FL commonly presents as widely spread systemic disease, and prognosis varies according to the extent of the disease and histologic grading at the time of diagnosis ([@b10-ol-0-0-8744]). In localized early stage diseases, watchful waiting or radiotherapy is available due to its slowly progressive nature, while chemotherapy including rituximab is selected in advanced stage diseases with high tumor burdens ([@b11-ol-0-0-8744]). The origin of tumor cells is germinal center B-cells which are heavily crowded in lymphoid organs, especially lymph nodes ([@b9-ol-0-0-8744]). Therefore, FL has been recognized as primary nodal lymphoma, and primary extranodal FL has been described in only a few organs including the skin and duodenum ([@b12-ol-0-0-8744]). The second part of the duodenum is known to be the most frequent site of FL of the GI tract followed by jejunum ([@b10-ol-0-0-8744]). In the latest revised fourth edition of WHO classification, duodenal FL was descried as a distinct variant of FL with typical clinical and immunophenotypical characteristics. However, in majority of cases, FL of the GI tract may present through secondary involvement by widespread nodal FL, therefore, primary gastric FL appears to be rare ([@b9-ol-0-0-8744],[@b10-ol-0-0-8744],[@b12-ol-0-0-8744],[@b13-ol-0-0-8744]--[@b17-ol-0-0-8744]). The present study describes 3 cases of gastric FL alongside a comprehensive review of previous cases reported in the literature and compares their features with those of duodenal FL.

Case report
===========

### Case selection

A total of 3 cases of gastric FL were retrieved from among the cases in the databases of 4 university hospitals in South Korea (SNU Hospital, SNU Boramae Hospital, SNU Bundang Hospital and Dongtan Sacred Heart Hospital Hallym University). The cases were selected from a total of 3,216 cases of non-Hodgkin\'s lymphoma of the GI tract, occurring between January 2000 and December 2015, as the only 3 cases of gastric FL. The pathological features were reviewed by 3 experienced hematopathologists. Due to the retrospective nature of the study, ethical approval and patient consent for publication was waived for the present study by the Institutional Review Board of Seoul National University Boramae Hospital (Seoul, South Korea).

### Case 1

A 61-year-old man was referred to SNU Boramae Hospital in November, 2015 for the management of a gastric lesion detected during an annual health check-up program at a local clinic. Endoscopic examination revealed a well demarcated, polypoid mass in the anterior wall of the gastric body. Despite three repeat biopsies, the preoperative pathological results remained unclear, simply suggesting a malignant lymphoma of germinal center B-cell origin. Constitutional symptoms, including lymphadenopathy, organomegaly and anemia, were not exhibited. A partial gastrectomy was performed and revealed a well demarcated, protruded mass, measuring 2.0×1.8-cm in the body, as well as an additional 1.5×1.2-cm nodule in the lesser omentum. Specimens were fixed using 10% formaldehyde for 24 h at room temperature and embedded in paraffin at room temperature for 24 h. Serial 4-µm-thick sections were sliced and were stained with 0.5% hematoxylin staining solution for 20 min at room temperature. Subsequently, 1% hydrochloric acid alcohol was added for 1 min. The slides were stained with 1% eosin Y staining solution for 1 min at room temperature and dehydrated at room temperature after applying tap water at room temperature for 15 min. and immunohistochemistry (IHC) for CD3 (clone F7.2.38, Dako; Agilent Technologies, Inc., Santa Clara, CA, USA; 1:600), CD5 (clone 4C7, DAKO; 1:100), CD20 (clone L26, Dako; Agilent Technologies, Inc: 1:200), BCL2 (clone 124, DAKO; Agilent Technologies, Inc.; 1:50), BCL6 (clone LN22, Leica Microsystems, Ltd., Milton Keynes, UK; 1:60), CD10 (clone 56C6, Leica Microsystems, Ltd; 1:30), CD23 (clone SP23, Thermo Fisher Scientific, Inc., Waltham, MA, USA; 1:100), CD43 (clone DF-T1, DAKO; 1:2,500), cyclin D1 (clone SP4, Thermo Fisher Scientific, Inc: 1:25) and MUM1 (clone EAU32, Leica Microsystems, Ltd; 1:100). IHC staining was performed using the Ventana Benchmark XT system (Ventana Medical Systems, Inc., Tucson, AZ, USA) or a Bond-Max automated immunostainer (Leica Microsystems, Ltd.). Sections were dried in oven at 60°C for 30 min and deparaffinized in xylene and rehydrated through a series of graded ethanol solutions (95, 85, 70 and 55%) at room temperature for 10 min. Antigen retrieval was performed in a pressure cooker at 95°C for 2 min using 0.01 M citrate buffer (pH 6.0) and incubated overnight at 4°C for all the primary antibodies. Then the slides were washed by phosphate buffered saline (PBS) four times. After warming to 37°C, detection involved ultraView Universal DAB Detection kit (cat. 760--500, Ventana Medical Systems, Inc.) that includes a cocktail of horseradish peroxidase-labeled goat anti-rabbit, mouse IgG secondary antibodies for 16 min. The complex was then visualized with 3,3′-diaminobenzidine tetrahydrochloride (DAB) chromogen according to the manufacturer\'s protocol. The samples were then analyzed by a BX51 light microscope (magnification, ×200 and ×400) (Olympus Corporation, Tokyo, Japan). Histologically, the two tumors comprised small-to medium-sized lymphoid cells with complete nodular architecture. Lymphoepithelial lesions and monocytoid or plasmacytoid features indicative of MALT lymphoma were not identified. The epicenter of the tumor was the submucosa, however, the tumor extended to the muscularis propria, with only focal involvement of the mucosa. Immunohistochemistry (IHC) indicated that the tumor cells were positive for cluster of differentiation CD10, CD20, B-cell lymphoma BCL2 and BCL6, and negative for CD3, CD5, CD23, CD43, cyclin D1 and mutated melanoma-associated antigen (MUM) 1/interferon regulatory factor (IRF)4. Follicular dendritic cell (FDC) networks were preserved within the CD21-positive nodules, demonstrating a predominantly compact pattern with focal abolishment at the center of the nodule ([Fig. 1](#f1-ol-0-0-8744){ref-type="fig"}). The patient was diagnosed with FL of grade 1--2 with a follicular pattern according to the WHO classification ([@b10-ol-0-0-8744]). A fluorescence *in situ* hybridization (FISH) test for locus-specific identifier immunoglobulin heavy chain (IGH)/BCL2 dual fusion translocation probe (Vysis; Abbott Pharmaceutical Co., Ltd., Lake Bluff, IL, USA) and BCL2 break-apart probe (Vysis; Abbott Pharmaceutical Co., Ltd.) revealed no rearrangement of BCL2 at 18q21 ([@b18-ol-0-0-8744]). The background gastric mucosa demonstrated prominent lymphoid follicles with Helicobacter pylori (H. pylori) colonization. As the omental tumor was interpreted as a multiplicity rather than a metastatic deposit, the patient\'s final clinical stage was IE2 using the modified Ann Arbor ([@b19-ol-0-0-8744],[@b20-ol-0-0-8744]) staging system, or I using the Lugano ([@b21-ol-0-0-8744]) staging system. The patient was treated with 6 cycles of chemotherapy \[intravenous (IV) rituximab 375 mg/m^2^, cyclophosphamide 750 mg/m^2^ IV, vincristine 1.4 mg/m^2^ IV and prednisolone 40 mg/m^2^ per oral (PO), R-CVP\] every 21 days. The patient came to hospital every month and remained disease-free at the last follow-up (13 months following diagnosis).

### Case 2

A 50-year-old man underwent gastroscopy for routine health check-up in Dongtan Sacred Heart Hospital and presented with a gastric lesion; a single elevated submucosal mass at the fundus, grossly indicative of a GI stromal tumor. As in the first case, no additional abnormalities were identified through systemic examination. The patient underwent a partial gastrectomy following an endoscopic biopsy that failed to provide a pathological diagnosis, which revealed a 1.8×1.6-cm submucosal tumor extending to the muscularis propria. The microscopic features and IHC results were near identical to those in case 1, with the exception of the absence of separate tumor nodule in the omentum. Rearrangement of BCL2 was not detected using the IGH/BCL2 dual fusion probe or BCL2 break-apart probe by FISH ([Fig. 2](#f2-ol-0-0-8744){ref-type="fig"}). The colonization of H. pylori was not identified in the surrounding gastric mucosa. The patient\'s final stage was IE2 using the modified Ann Arbor staging system ([@b19-ol-0-0-8744],[@b20-ol-0-0-8744]) and stage I using the Lugano staging system ([@b21-ol-0-0-8744]). The patient refused any further treatment and remained disease-free for 30 months following the surgery. Subsequently, the patient was lost to but follow-up.

### Case 3

A 40-year-old man presented with epigastric discomfort for several months. An endoscopy performed on December, 2015 at Seoul National University Hospital (Seoul, Korea) revealed multiple elevated mass-like lesions at the mid-body of the stomach, on the lesser curvature side, and a biopsy confirmed FL of grade 1--2 with a predominantly diffuse pattern. Unlike the 2 aforementioned cases, the subepithelial lamina propria was densely filled with small-to medium-sized lymphoid cells without nodular aggregation. Despite extensive lymphoid infiltration, definite lymphoepithelial lesions were not identified. The tumor cells were positive for CD10, CD20, BCL2 and BCL6, and negative for CD3, cyclin D1 and MUM1/IRF4, according to the IHC results. The tumor cells were also positive for IGH/BCL2 translocation, as confirmed by FISH ([Fig. 3](#f3-ol-0-0-8744){ref-type="fig"}). In addition to the gastric lesion, multiple large hypermetabolic lymph nodes (≤12.0 cm) were identified in the retroperitoneum, mesentery and abdomen. A bone marrow examination revealed the involvement of FL. The patient\'s final stage was IVA using the Ann Arbor staging system ([@b10-ol-0-0-8744],[@b18-ol-0-0-8744]). It was concluded that the gastric lesion was possibly secondary to nodal FL, due to the presence of massive lymphadenopathy. The patient underwent 6 cycles of R-CVP (rituximab 375 mg/m^2^ IV, cyclophosphamide 750 mg/m^2^ IV, vincristine 1.4 mg/m^2^ IV and prednisolone 40 mg/m^2^ PO) every 21 days without surgical intervention, demonstrating partial response on computed tomography (CT) scan. Following R-CVP, he received 9 cycles of rituximab maintenance therapy (750 mg/m^2^ IV every 2 months) and showed complete response. At time of publication, he is planning to undergo 3 more cycles of maintenance chemotherapy (26 months post-diagnosis).

Discussion
==========

FL is a basic nodal-based neoplasm, although several cases of primary extranodal FL have previously been described as specific variants ([@b10-ol-0-0-8744],[@b12-ol-0-0-8744],[@b13-ol-0-0-8744]--[@b15-ol-0-0-8744]). Involvement of the GI tract by advanced nodal FL may be uncommon, although accurate incidence rates have not been reported ([@b22-ol-0-0-8744]). Among extranodal FL, primary gastric FL is rare. According to a nationwide survey of malignant lymphoma among Koreans released in 2011 ([@b8-ol-0-0-8744]), there was no single case of gastric FL in the 1,112 recorded cases of GI lymphoma. To date, \<20 cases of primary gastric FL with well documented pathological results have been reported in the literature, although the overall incidence should be slightly higher ([Table I](#tI-ol-0-0-8744){ref-type="table"}) ([@b13-ol-0-0-8744],[@b16-ol-0-0-8744],[@b23-ol-0-0-8744]--[@b25-ol-0-0-8744]). Due to the higher incidence of MALT lymphoma in stomach, and the similar cytologic morphology of tumor cells of MALT lymphoma and FL, primary gastric FL may have been misdiagnosed as MALT lymphoma, especially in small biopsy specimens. Based on a review of previous studies, the majority of gastric FL presented as single- or multiple-polypoid submucosal masses, which could hinder the accurate diagnosis through endoscopic mucosal biopsy. Histologically, the tumor cells were of low grade, consistent with grade 1--2 and exhibited a predominantly follicular pattern, similar to those observed in 2 of the cases described in the present study. In contrast to cases 1 and 2, case 3 was confirmed as FL by endoscopic biopsy due to diffuse tumor cell infiltration in the lamina propria. This diffuse mucosal involvement may be a useful feature to differentiate secondary involvement by nodal FL from primary gastric FL. Takata *et al* ([@b13-ol-0-0-8744],[@b14-ol-0-0-8744]) suggested that an FDC pattern can help differentiate primary duodenal FL from nodal FL by performing IHC for FDC markers (CD23 or CD43); loss of FDC network in the center, with remnant peripheral FDC exhibiting a 'hollow pattern' is identified in duodenal FL, whereas a compact nodular network of FDCs is exhibited in nodal FL. The FDCs are reported to provide a growth advantage to FL cells by interacting with tumor cells. The hollow pattern may be associated with relatively lower histologic grade and the indolent clinical nature of duodenal FL ([@b15-ol-0-0-8744]). In contrast, case 1 of the present study exhibited preserved FDC nodules, while case 2 revealed near complete loss of FDCs without peripheral accentuation; these patterns differ from the typical hollow pattern of duodenal FL previously reported ([@b13-ol-0-0-8744]--[@b15-ol-0-0-8744]). Case 3 also exhibited an absence of an FDC network, similar to case 2. Therefore, the 'hollow pattern' does not appear to be specific to primary gastric FL. Rather, a preserved FDC network may be interpreted as a phenomenon associated with disease progression.

The majority of reported primary gastric FL cases presented with a localized extent of disease. In the present case report, defining the pathological staging of case 1 was difficult due to a concomitant omental tumor nodule without regional lymph node involvement. According to the Tumor-Node-Metastasis staging of the American Joint Committee on Cancer, an omental nodule may be interpreted as a regional lymph node metastasis (N1) or a subserosal invasion (T3) ([@b26-ol-0-0-8744]). However, there was little evidence of extrafollicular invasion, as observed in the CD10 IHC results in the gastric and omental lesions. Therefore, the omental tumor may be interpreted as multiplicity rather than as a metastatic deposit. Multifocality is one of the well-known characteristics in duodenal FL ([@b27-ol-0-0-8744]). It was concluded that case 3 of the present study was most likely a secondary involvement of the stomach based on Dawson\'s criteria of primary GI lymphoma ([@b28-ol-0-0-8744]), and the final stage was designated stage IV due to bone marrow involvement. Unlike primary gastric FLs, secondary gastric involvement may occur in the advanced stage of nodal FL.

Certain studies have identified the lack of BCL2 translocation in primary cutaneous FL as a distinctive feature that differentiates it from nodal FL, suggesting distinct tumorigenic processes in extranodal sites ([@b29-ol-0-0-8744]). This conclusion was not supported in GI FL; a number of previous studies have identified BCL2 rearrangement in primary intestinal FL ([@b12-ol-0-0-8744],[@b23-ol-0-0-8744]). However, the incidence of BCL2 translocation in primary gastric FL was decreased compared with that in nodal FL, or even duodenal FL, although the expression of BCL2 protein was consistently observed ([@b2-ol-0-0-8744]). The 2 primary gastric FL cases described in the present study were negative for BCL2 translocation, whereas the case of secondary involvement of nodal FL exhibited translocation t(14;18). It is possible that the absence of translocation t(14;18) may serve as a diagnostic indicator, differentiating primary gastric FL from nodal FL. However, this decreased tendency for BCL2 translocation may be as a result of the under-recognition of FL disguised as MALT lymphoma. Nevertheless, translocation-negative cases also revealed an overexpression of BCL2 protein, similar to previous studies, suggesting an alternative genetic mechanism rather than an IGH/BCL2 rearrangement ([@b30-ol-0-0-8744]).

To the best of our knowledge, there has been no proven etiological agent for gastric FL identified to date, although a number of studies presume that local immunity will contribute to the pathogenesis of FL of the GI tract, just as *H. pylori* participates in the development of MALT lymphoma ([@b31-ol-0-0-8744]). Local antigen-experienced B-cells are suggested to be the origin of primary FL of the GI tract based on the frequent expression of IgA and the α4β7 mucosal homing receptor in the tumor cells ([@b32-ol-0-0-8744]). Colonization of *H. pylori* was identified in case 1 and 3 of the present case report, and Hatano *et al* ([@b17-ol-0-0-8744]) revealed an \~50% incidence of *H. pylori* in gastric FLs in patients of Japanese origin. Considering that the seropositivity for *H. pylori* is \~54% in patients of Korean origin ([@b33-ol-0-0-8744]), the causal association of *H. pylori* in gastric FL is not robust enough to be conclusive. However, in case 1 of the present study, follicular gastritis was present in the background mucosa, suggesting the involvement of *H. pylori* in the tumorigenesis of gastric FL. Although antibiotics targeting *H. pylori* in FL failed in a considerable proportion of patients, there were also a limited number of patients that achieved complete remission ([@b34-ol-0-0-8744]). Nevertheless, there may be a subgroup of gastric FL associated with a local antigen-presenting environment such as *H. pylori* infection, however, further studies are required to elucidate such cases.

Although the vast majority of GI FLs demonstrate a limited disease extent at the time of diagnosis unlike nodal FLs, the prognosis of gastric FLs does not appear to differ from that of nodal FLs considering the relatively indolent behavior of nodal FLs, even in advanced stages reported in previous studies ([@b1-ol-0-0-8744],[@b2-ol-0-0-8744],[@b10-ol-0-0-8744],[@b16-ol-0-0-8744],[@b24-ol-0-0-8744],[@b25-ol-0-0-8744],[@b35-ol-0-0-8744]). Based on a review of gastric FLs, including 2 cases from the present study, no disease relapses or disease-associated mortalities have been reported ([@b13-ol-0-0-8744],[@b16-ol-0-0-8744],[@b23-ol-0-0-8744]--[@b25-ol-0-0-8744]). Due to this indolent behavior, despite heterogeneous treatment modalities, therapeutic interventions are recommended only in symptomatic or progressive cases ([@b36-ol-0-0-8744]). In contrast to the majority of nodal FLs that acquire additional genetic alterations leading to widespread disease and high-grade transformation, FL cells of the GI tract tend to reside in the primary site, potentially explaining the indolent nature of the tumor. There are several reports of gastric FLs with a co-existing diffuse large B-cell lymphoma component, yet such patients generally had favorable disease courses ([@b23-ol-0-0-8744],[@b37-ol-0-0-8744]).

The main differential diagnosis of FL in the GI tract includes florid lymphoid hyperplasia, MALT lymphoma, mantle cell lymphoma and secondary involvement of nodal FL. A distinction from reactive lymphoid hyperplasia may be made in the same context as nodal lesions, where monomorphic composition, absence of tangible body macrophages and architectural disruption favor FL. Occasionally, MALT lymphoma or mantle cell lymphoma is dominated by small lymphocytes with a nodular architecture. Tumor cells in MALT lymphoma present a characteristic lymphoepithelial lesion, which is uncommon in the majority of FL cases ([@b2-ol-0-0-8744],[@b10-ol-0-0-8744],[@b23-ol-0-0-8744],[@b27-ol-0-0-8744],[@b36-ol-0-0-8744]). However, there has been one study of gastric FL with a lymphoepithelial lesion resembling MALT lymphoma ([@b24-ol-0-0-8744]). Furthermore, certain cases of gastric FL with diffuse mucosal involvement lacking BCL translocation may easily be misinterpreted as MALT lymphoma, particularly in small biopsy specimens ([@b38-ol-0-0-8744]). Under these circumstances, IHC results usually provide clear distinctions between these types of tumor cell. Neoplastic cells in MALT lymphoma present with negative BCL6 and CD10 IHC test results. As for mantle cell lymphoma, CD5 and cyclin D1 may assist in forming the correct diagnosis. For determining the secondary involvement of nodal FL, Dawson\'s criteria for primary GI lymphoma should be applied ([@b1-ol-0-0-8744]).

In conclusion, primary gastric FL is a rare, under-recognized disease. Although the general prognosis is indolent, similar to that of nodal FL, a lack of BCL2 rearrangement, low-grade histology with a follicular pattern and sparse mucosal involvement may serve as diagnostic indicators for excluding secondary involvement by nodal FL.
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![Representative features of case 1, primary gastric follicular lymphoma. (A) An endoscopy and (B) the resected specimen revealed a well demarcated polypoid mass in the gastric body. Microscopically, nodular aggregates of small lymphoid cells in the submucosa with little mucosal involvement are characteristic, as demonstrated by hematoxylin and eosin staining at (C) ×10 and (D) magnification, ×40. (E) Tumor cells were positive for CD10 (magnification, ×40). (F) The follicular dendritic cell network was preserved, using anti-CD21 (magnification, ×40). The omental nodule revealed similar results following (G) hematoxylin and eosin and (H) anti-CD10 staining (magnification, ×40). CD, cluster of differentiation.](ol-16-01-0741-g00){#f1-ol-0-0-8744}

![Representative features of case 2, primary gastric follicular lymphoma. Microscopic results identified follicular lymphoma centered in the submucosa at (A) ×10 and (B) ×40 magnification using hematoxylin and eosin staining. (C) No follicular dendritic cells were identified using anti-cluster of differentiation 21 (magnification, ×40). (D) Tumor cells expressed BCL2 protein (magnification, ×400), however, (E) the majority of tumor cells exhibited two, split, red and green signals in fluorescence *in situ* hybridization using a dual fusion probe. BCL2, B-cell lymphoma 2.](ol-16-01-0741-g01){#f2-ol-0-0-8744}

![Case 3 was suspected to be a secondary involvement of nodal follicular lymphoma. (A) An endoscopy revealed multiple protruded lesions with erosions. Microscopically, tumor cells diffusely infiltrated the mucosa, without lymphoepithelial lesions, as stained by hematoxylin and eosin and imaged at (B) ×200, and (C) ×400 magnification. Tumor cells were positive for (D) cluster of differentiation 10 and (E) BCL6 (magnification, ×400). (F) immunoglobulin heavy locus/BCL2 translocation was revealed by fluorescence *in situ* hybridization study using a dual fusion probe. BCL2, B-cell lymphoma 2.](ol-16-01-0741-g02){#f3-ol-0-0-8744}

###### 

Summarized clinicopathological parameters of cases of gastric follicular lymphoma in the literature.

  First author, year       Age, years   Sex                Multiplicity   Grade                                                                                          t(14:18)   *H. pylori*   Stage^[a](#tfn1-ol-0-0-8744){ref-type="table-fn"}^   Treatment            Outcome, months   (Refs.)
  ------------------------ ------------ ------------------ -------------- ---------------------------------------------------------------------------------------------- ---------- ------------- ---------------------------------------------------- -------------------- ----------------- ----------------------
  Present case             61           M                  No             1--2                                                                                           No         Yes           I                                                    R-CVP                NED, 8            
                           50           M                  No             1--2                                                                                           No         No            I                                                    Surgery only         NED, 30           
                           40           M                  Yes            3^[a](#tfn1-ol-0-0-8744){ref-type="table-fn"}^                                                 Yes        Yes           IV                                                   R-CVP                PR, 6             
  Takata *et al*, 2013     51--81       M (n=4), F (n=4)   Unknown        1--2                                                                                           3/8        Unknown       I (n=5), II (n=2), IV (n=1)                          Unknown              Unknown           ([@b9-ol-0-0-8744])
  Tzankov *et al*, 2002    72           F                  No             1--2                                                                                           Yes        Unknown       I                                                    CHOP                 NED, 13           ([@b24-ol-0-0-8744])
  Huang *et al*, 2002      48           F                  No             3^[a](#tfn1-ol-0-0-8744){ref-type="table-fn"},\ [b](#tfn2-ol-0-0-8744){ref-type="table-fn"}^   Unknown    Unknown       IIE                                                  CEOP                 NED, 70           ([@b23-ol-0-0-8744])
  Kanda *et al*, 2002      57           F                  Yes            1--2                                                                                           Yes        Unknown       I                                                    Surgery only         NED, 15           ([@b16-ol-0-0-8744])
  Iwamuro *et al*, 2002    73           M                  No             1                                                                                              No         Yes           IIE                                                  Surgery and R-CHOP   NED, 30           ([@b25-ol-0-0-8744])
  Misdragi *et al*, 2002   67           F                  Yes            1--2                                                                                           No         No            I                                                    Rituximab            MOC, 48           ([@b27-ol-0-0-8744])

Staged by the Lugano system.

Diffuse large B-cell lymphoma component present. R, rituximab; CVP, cyclophosphamide, vincristine and prednisolone; CEOP, cyclophosphamide, epirubicin, vincristine and prednisolone; CHOP, cyclophosphamide, doxorubicin, oncovin and prednisone; NED, no evidence of disease; PR, partial remission; MOC, mortality from other causes; *H. pylori, Helicobacter pylori*.

[^1]: Contributed equally
